January 16th, 2016.
LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series B Round of ViCentra B.V., a private Dutch company commercializing the Kaleido insulin pump system for people with diabetes.
The syndicate, led by LSP with participation from existing investor INKEF will invest EUR 10 million. The funding will support European commercialization of the Kaleido system and preparations for US market entry. As part of the financing, Anne Portwich and Jörg Neermann, both partners, LSP, will join ViCentra’s supervisory board.
Driven by ViCentra’s belief in the power of innovative healthcare products that put the people who use them first and a desire to be meaningfully different, Kaleido aims to reduce the impact that diabetes can have on daily life. Utilizing Bluetooth wireless technology, Kaleido will infuse color and choice into the market, networking its hybrid patch pumps and handsets into a broader family of easy-to-use products and data services to create a customer-focused, integrated diabetes support service. Setting its sights on expanding insulin pump usage by appealing to both first time and experienced insulin pump users, Kaleido will launch in selected European territories over the course of 2016.